Business
Peter Melnyk Joins Taiho Oncology as President & Chief Operating Officer
PRINCETON, N.J., January 20, 2026--Peter Melnyk joins Taiho Oncology as President & Chief Operating Officer.
About this update from Alpha Tau Medical Ltd.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":252,"url":"https://media.zenfs.com/en/business-wire.com/d9ba9b6a14d7c013afddc0d5c980d378"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qxRAmOoaV.tTaJlDZiL75A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUwNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d9ba9b6a14d7c013afddc0d5c980d378","width":480,"height":252}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Mr. Melnyk has more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors.","length":160,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":160,"olType":false},{"type":"text","content":"PRINCETON, N.J., January 20, 2026--(BUSINESS WIRE)--Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors, announced today Peter Melnyk has joined the company as President & Chief Operating Officer.","length":274,"tagName":"p"},{"type":"text","content":"Mr. Melnyk comes to Taiho Oncology with more than 30 years of proven experience in oncology commercialization and leadership across pharmaceuticals, medical devices and biotech sectors. Mr. Melnyk joined Taiho Oncology from Alpha Tau Medical, where he was the Chief Commercial Officer and former board member and led the global commercialization efforts for a novel alpha-emitting radiotherapeutic. He was also the CEO of Fortovia Therapeutics and drove the transformation and portfolio expansion in oncology supportive care. In addition, Mr. Melnyk was the Chief Commercial Officer at Novocure, where he built the global commercial infrastructure and launched Optune, a novel medical device for the treatment of glioblastoma. He also held senior leadership roles at OSI/Astellas, Pharmacia/Pfizer and Bristol-Myers Squibb and holds a Master of Science and Bachelor of Science from McGill University.","length":900,"tagName":"p"},{"type":"text","content":""We are excited to welcome Peter to Taiho Oncology as President & Chief Operating Officer," said Tim Whitten, CEO of Taiho Oncology. "Peter is an innovator with a demonstrated track record of success. We believe his strong leadersh...